RTW Investments LP Boosts Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

RTW Investments LP boosted its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 10.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,123,525 shares of the company's stock after acquiring an additional 471,240 shares during the period. RTW Investments LP owned 9.67% of Stoke Therapeutics worth $56,512,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. KLP Kapitalforvaltning AS purchased a new stake in Stoke Therapeutics during the 4th quarter valued at about $63,000. Teacher Retirement System of Texas purchased a new stake in Stoke Therapeutics during the 4th quarter valued at about $113,000. China Universal Asset Management Co. Ltd. purchased a new stake in Stoke Therapeutics during the 4th quarter valued at about $124,000. Tower Research Capital LLC TRC grew its stake in Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock valued at $132,000 after acquiring an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. purchased a new stake in Stoke Therapeutics during the 4th quarter valued at about $133,000.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on STOK. Chardan Capital reissued a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. HC Wainwright lowered their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Finally, Needham & Company LLC reissued a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Stoke Therapeutics presently has an average rating of "Buy" and a consensus target price of $23.20.

Insider Transactions at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the sale, the insider now owns 63,962 shares of the company's stock, valued at approximately $554,550.54. This represents a 5.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the sale, the director now owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is currently owned by corporate insiders.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK traded up $0.07 during mid-day trading on Monday, reaching $9.83. 875,593 shares of the company were exchanged, compared to its average volume of 715,180. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $17.58. The firm's 50-day simple moving average is $8.16 and its 200 day simple moving average is $9.94. The firm has a market cap of $536.69 million, a price-to-earnings ratio of -4.68 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.38. The business had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.